Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Longterm Growth with Eight Ph 2 and Ph 3 Data Readouts in 202021 and One New IND Per Year for the Next 5 Years

Initiation of etrasimod Ph 23 program in Crohn's disease CD Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis EoE and alopecia areata AA First subject dos...